Amid crowded migraine market, Lundbeck goes its own wayThe market for migraine treatment and prevention has been transformed by the launch of several new drugs targeting Share XAmid crowded migraine market, Lundbeck goes its own wayhttps://pharmaphorum.com/news/amid-crowded-migraine-market-lundbeck-goes-its-own-way/
Pfizer strikes $1.2bn licensing deal for Biohaven migraine drugPfizer has bolstered its central nervous system (CNS) drugs portfolio with a $1.2 billion deal to claim rights Share XPfizer strikes $1.2bn licensing deal for Biohaven migraine drughttps://pharmaphorum.com/news/pfizer-strikes-1-2bn-licensing-deal-for-biohaven-migraine-drug/
AbbVie’s Qulipta cleared for migraine prevention, setting up Biohaven clashAbbVie has added a third drug to its arsenal in the crowded migraine market, getting FDA approval for Share XAbbVie’s Qulipta cleared for migraine prevention, setting up Biohaven clashhttps://pharmaphorum.com/news/abbvies-qulipta-cleared-for-migraine-prevention-setting-up-biohaven-clash/
Could personalised medicine change treatment for migraine?The concept of personalised medicine is becoming established in cancer, with an increasing number of drugs targeting specific Share XCould personalised medicine change treatment for migraine?https://pharmaphorum.com/views-and-analysis/could-personalised-medicine-change-treatment-for-migraine/
Stress not a significant factor in migraine attacks, study findsNew findings from a digital study have challenged the belief that stress is a significant factor in triggering Share XStress not a significant factor in migraine attacks, study findshttps://pharmaphorum.com/news/stress-not-a-significant-factor-in-migraine-attacks-study-finds/
Novartis’ Aimovig tops topiramate in migraine face-offNovartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to Share XNovartis’ Aimovig tops topiramate in migraine face-offhttps://pharmaphorum.com/news/novartis-aimovig-tops-topiramate-in-migraine-face-off/
Salvia’s migraine implant could be breakthrough, says FDAAn implantable neurostimulation migraine device from Salvia BioElectronics has gained Breakthrough Device Designation from the FDA. Traditional neurostimulation Share XSalvia’s migraine implant could be breakthrough, says FDAhttps://pharmaphorum.com/news/salvias-migraine-implant-could-be-breakthrough-says-fda/
Lundbeck tops Q3 expectations following strong sales of mental health drugsDenmark’s Lundbeck has beat its expectations in third quarter results, following a strong performance from its portfolio of Share XLundbeck tops Q3 expectations following strong sales of mental health drugshttps://pharmaphorum.com/news/lundbeck-tops-q3-expectations-following-strong-sales-of-mental-health-drugs/
Headache for Zosano as FDA turns down migraine patchZosano Pharma has been hit by an FDA rejection of its marketing application for migraine drug Qtrypta, asking Share XHeadache for Zosano as FDA turns down migraine patchhttps://pharmaphorum.com/news/headache-for-zosano-as-fda-turns-down-migraine-patch/
